Phase III Data of Antibody-Drug Conjugate Shows PFS Increase in HER2+ Disease
Continous Hormone Therapy Superior To Intermittent In 17-Year SWOG Study
Phase III Afatinib Trial Met Primary Endpoint In Stage IIIb or IV Cancer with EGFR Mutation
Phase III Regorafenib Trial Meets PFS Primary Endpoint
Radium-233 Dichloride Increased Overall Survival in Phase III Trial
Zytiga Plus Prednisone Shows Improvement in PFS and OS Over Prednisone Alone
Nexavar Phase III Trial Fails To Meet Primary Endpoint
Alimta/Cisplatin Chemotherapy Increased Overall Survival
New Carfilzomib Combination Produces Near Remissions
Trial Data: No Benefit In Adding Perifosine to Capecitabine
Blinatumomab Demonstrates High Response Rate in ALL
MET Inhibitor Improved Time To Progression by 56 Percent
NCI-Approved CTEP Trials For The Month of June
Trending Stories
- Knight Cancer Institute receives record-setting $2B gift from the Knights—and self-governance within OHSU
Brian Druker returns to executive role as president of the new Knight Cancer Group - Gardiner Harris, acclaimed health care and pharma journalist, on his New York Times bestselling book
- ACOG says it will no longer accept federal funding
- Duke Officials Silenced Med Student Who Reported Trouble in Anil Potti’s Lab
- The Med Student’s Memo – Research Concerns
- FY25 paylines drop to 4th percentile—a historic low—as NCI braces for Trump’s FY26 budget cuts
